D.E. Shaw & Co
TSHA icon

D.E. Shaw & Co’s Taysha Gene Therapies TSHA Stock Holding History

D.E. Shaw & Co’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30M Sell
4,398,652
-28,649
-0.6% -$170K 0.01% 1044
2026
Q1 		$19.8M Buy
4,427,301
+413,666
+10% +$1.92M 0.01% 1151
2025
Q4 		$22.1M Buy
4,013,635
+1,307,201
+48% +$6.35M 0.01% 1190
2025
Q3 		$8.85M Buy
2,706,434
+2,304,925
+574% +$6.53M 0.01% 1787
2025
Q2 		$927K Buy
+401,509
New +$872K ﹤0.01% 3288
2022
Q4 		– Sell
-107,274
Closed -$207K – 5132
2022
Q3 		$207K Sell
107,274
-27,311
-20% -$99.1K ﹤0.01% 4465
2022
Q2 		$501K Buy
134,585
+59,851
+80% +$237K ﹤0.01% 4086
2022
Q1 		$487K Buy
+74,734
New +$559K ﹤0.01% 4383
2021
Q3 		– Sell
-11,448
Closed -$243K – 5245
2021
Q2 		$243K Buy
+11,448
New +$264K ﹤0.01% 4373

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co's TSHA Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Taysha Gene Therapies (TSHA) stake by 0.65% in Q2 2026, selling an estimated $170K and leaving 4,398,652 shares worth $30M. The position accounts for 0.01% of the portfolio, ranked #1044.

D.E. Shaw & Co first reported a position in TSHA in Q2 2021 and has held it in 9 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • D.E. Shaw & Co held 4,398,652 shares of Taysha Gene Therapies worth $30M as of Q2 2026.
  • D.E. Shaw & Co sold 28,649 Taysha Gene Therapies shares in Q2 2026, an estimated $170K.
  • Taysha Gene Therapies made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1044 holding.
  • D.E. Shaw & Co first reported a position in Taysha Gene Therapies in Q2 2021 and has held it in 9 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.